Vioxx debacle: A class effect?

October 6, 2004

NEJM with two early release articles. One by cardiologist Eric Topol, and the other questioning whether Celebrex and other COX-2’s have similar cardiovascular risk.



Related posts:

  1. Topol on Russert
  2. The left-leaning NEJM
  3. COURAGE trial: The NEJM strikes back
  4. Primary care: "Second class citizens"
  5. Does aspirin prevent fatal heart attack and stroke?
  6. Pharmacogenomics: "Physicians are the sitting ducks in this new class of litigation"
  7. Stents and the COURAGE trial


KevinMD.com on Facebook


  Follow on Twitter   Subscribe



Comments on this entry are closed.

Previous post: The repercussions of the flu vaccine shortage

Next post: CNN news, brought to you by Ambien

Site Meter